Future studies should follow subjects during a washout period to determine if this effect helps maintain long-term weight control (i.e. minimize weight re-gain). Additionally, a future investigation should include a METABO only group with dietary control and no structured exercise program to explore the role of diet with METABO alone on body composition and metabolic outcomes. Neither placebo nor METABO administration

affected concentrations of blood lipids, including cholesterol, HDL, LDL, cholesterol/HDL ratio and TAG, although there was a strong trend (p < 0.07) for TAG concentrations to decrease more in the METABO group (-15.9%) compared to the placebo PLX3397 datasheet group (-2.6%). Future studies may attempt to explore this observation further with studies designed to look for differences in these important metabolic and biochemical markers as primary outcome measures. Another important finding in our study relates to the observed differences in adipokine concentrations in the METABO group, although most

of these did not achieve statistical significance. For example, we observed NU7441 in vitro a trend for decreased serum resistin concentrations in subjects who LY294002 price received METABO compared to placebo at week 4, but not week 8. High serum resistin concentrations have been found in obese individuals and have been linked to insulin resistance, hence the trend for decreased resistin levels Amoxicillin in METABO is an intriguing finding that requires further investigation in a future study [33]. The current study may have been underpowered to detect significant differences in serum adiponectin, given

that fat loss occurred in both groups as a result of caloric restriction and a consistent exercise program. In addition, trends for maintaining elevated serum leptin (from week 0 to week 4) were observed in subjects who received METABO compared to placebo. Leptin acts on receptors in the hypothalamus to regulate appetite, energy expenditure, sympathetic tone and neuroendocrine function, and circulating levels have been shown to decline in response to caloric restriction or negative energy balance [34]. Leptin deficiency has been shown to promote hunger and food seeking behaviour, in addition to reduced metabolic rate in humans [35]. Collectively, the trend for resistin and significant change in leptin may help to partly explain the effects of METABO on body composition. The combination of ingredients with potentially complementary and interactive mechanisms of action may account for the favorable changes observed in many of the clinical endpoints in the METABO group.